Dr. Matthew Halpert earned his doctorate at the University of Alabama-Birmingham (UAB), and then spent 10 years at Baylor College of Medicine in Houston as a Cancer Immunologist. During his research, Dr. Halpert published research in some of the most prestigious peer-reviewed journals, has been cited over 450 times, and became one of the leading experts regarding cutting-edge cancer immunotherapy.
Additionally, he has founded Diakonos Oncology, which is currently studying its revolutionary Dendritic Cell Treatment in multiple FDA clinical trials, including Glioblastoma which recently was awarded a &#8220;Fast Track&#8221; designation from the FDA (in 2023) and won a &#8220;Breakthough in Cancer&#8221; award (in 2024). Other trials are on the same projectile, and there is optimism for future approvals.
In 2021, Dr. Halpert left Baylor College of Medicine to found the Immunocine Cancer Center, which leverages the Dendritic Cell Treatment currently being studied in US trials for patients that may benefit &#8216;today&#8217; but are not eligible for one of the trials and do not have the time to wait.

Matthew Halpert, PhD